How Does Sitavig Work?
Sitavig delivers concentrated medication that stays localized at the site of viral replication in the mouth. Patients treated with a single dose of Sitavig went an average of 304 days before their next cold sore outbreak compared with an average of 199 days for patients treated with a placebo.¹*
Patients also experienced significant relief from cold sore symptoms in just 3.5 days and completely healed in 5.5 days, when Sitavig was applied within 1 hour of feeling the sensation and before the blister appeared.¹*
Be prepared
Even if you have no signs of a cold sore, it’s smart to see your healthcare provider and ask for Sitavig. Go ahead and get your Sitavig prescription filled and keep your Sitavig tablet with you at all times.
Additional cold sore resources:
*Data on the incidence and delay of the next recurrence need further confirmation as they were obtained on a subset of patients.
References
- Bieber T, Chosidow O, Bodsworth N, Tyring S, Hercogova J, Bloch M, Davis M, Lewis M, Boutolleau D, Attali P and the LIP Study Group. Efficacy and safety of acyclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP): A double-blind, placebo-controlled, self-initiated trial. J Drugs Dermatol. 2014;13(7):791-798. View study (link will lead you to the JDD site).
Indication & Important Safety Information
INDICATION
Sitavig® (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for
the treatment of recurrent herpes labialis (cold sores) in immunocompetent
adults.
IMPORTANT SAFETY INFORMATION
- Sitavig should not be used in patients with known hypersensitivity to acyclovir, milk protein concentrate, or other components of the product.
- Sitavig has not been studied in pregnant women or in immunocompromised patients and no interaction studies have been performed. Sitavig’s safety and efficacy have not been established in pediatric patients.
- Sitavig is a Pregnancy Category B product; therefore it should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. It is not known if Sitavig is excreted in breast milk; however, systemic absorption is minimal.
- In a controlled clinical trial Sitavig’s most common side effects (greater than or equal to 1%) were: headache (3%), dizziness (1%), lethargy (1%), gingival (gum) pain (1%), aphthous stomatitis (canker
sores) (1%), application site pain (1%), application site irritation (1%), erythema (1%) and rash (1%). In the same trial these side effects ranged from 0%-3% for placebo.
You are encouraged to report negative side effects of prescription
drugs to the FDA. Visit www.fda.gov/medwatch.com or call
1-800-FDA-1088. Click here for Full Prescribing Information.
